zealand_logo_RGB_01.png
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
June 13, 2024 11:00 ET | Zealand Pharma
Company announcement – No. 31 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 13, 2024 – Zealand Pharma A/S (“Zealand”)...
zealand_logo_RGB_01.png
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:38 ET | Zealand Pharma
Company announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of...
zealand_logo_RGB_01.png
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
June 06, 2024 06:29 ET | Zealand Pharma
Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark,...
zealand_logo_RGB_01.png
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
May 31, 2024 10:03 ET | Zealand Pharma
Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency ...
zealand_logo_RGB_01.png
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
May 29, 2024 11:10 ET | Zealand Pharma
Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....
zealand_logo_RGB_01.png
Zealand Pharma major shareholder announcement: Polar Capital
May 29, 2024 07:32 ET | Zealand Pharma
Company announcement – No. 28 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 29 May 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50...
zealand_logo_RGB_01.png
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
May 23, 2024 14:45 ET | Zealand Pharma
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the First Quarter of 2024
May 16, 2024 01:00 ET | Zealand Pharma
Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data...
zealand_logo_RGB_01.png
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
May 12, 2024 16:00 ET | Zealand Pharma
Company announcement – No. 25 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
zealand_logo_RGB_01.png
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
May 09, 2024 10:00 ET | Zealand Pharma
Press Release – No. 4 / 2024 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results Copenhagen, Denmark, May 9, 2024 – Zealand Pharma...